CNS Pharmaceuticals Key Executives
This section highlights CNS Pharmaceuticals's key executives, including their titles and compensation details.
Find Contacts at CNS Pharmaceuticals
(Showing 0 of )
CNS Pharmaceuticals Earnings
This section highlights CNS Pharmaceuticals's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
$1.28
Stock Price
$3.75M
Market Cap
3
Employees
Houston, TX
Location
Financial Statements
Access annual & quarterly financial statements for CNS Pharmaceuticals, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- |
| Cost of Revenue | $4.13K | $11.76K | $13.07K | $11.10K | $1.96K |
| Gross Profit | $-4.13K | $-11.76K | $-13.07K | $-11.10K | $-1.96K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $14.10M | $9.30M | $9.35M | $5.06M | $1.85M |
| General and Administrative Expenses | $4.77M | $5.97M | $4.68M | $4.39M | $1.98M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $4.77M | $5.97M | $4.68M | $4.39M | $1.98M |
| Other Expenses | $- | $- | $- | $- | $- |
| Operating Expenses | $18.87M | $15.27M | $14.03M | $9.45M | $3.83M |
| Cost and Expenses | $18.87M | $15.27M | $14.03M | $9.45M | $3.83M |
| Interest Income | $13.88K | $7 | $9 | $3 | $44 |
| Interest Expense | $- | $7.03K | $9.29K | $3.26K | $44.23K |
| Depreciation and Amortization | $4.13K | $11.76K | $13.07K | $11.10K | $1.96K |
| EBITDA | $-18.86M | $-15.26M | $-14.47M | $-9.44M | $-3.83M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-18.87M | $-15.27M | $-14.03M | $-9.45M | $-3.83M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $13.88K | $-7.03K | $-9.29K | $-3.26K | $-44.23K |
| Income Before Tax | $-18.85M | $-15.27M | $-14.04M | $-9.46M | $-3.88M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $- | $7.03K | $9.29K | $3.26K | $42.28K |
| Net Income | $-18.85M | $-15.27M | $-14.50M | $-9.46M | $-3.88M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-251.35 | $-560.83 | $-852.66 | $-859.81 | $-353.57 |
| EPS Diluted | $-250.19 | $-560.83 | $-825.04 | $-853.68 | $-353.57 |
| Weighted Average Shares Outstanding | 75.00K | 27.23M | 17.00M | 11.00M | 10.97M |
| Weighted Average Shares Outstanding Diluted | 75.35K | 27.23M | 17.57M | 11.08M | 10.97M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $6.36K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $752 | $818 | $953 | $899 | $1.00K | $1.28K | $2.38K | $2.79K | $3.21K | $3.38K | $3.49K | $3.37K | $3.21K | $3.00K | $- | $- | $- | $- | $- |
| Gross Profit | $- | $-752 | $-818 | $5.41K | $-899 | $-1.00K | $-1.28K | $-2.38K | $-2.79K | $-3.21K | $-3.38K | $-3.49K | $-3.37K | $-3.21K | $-3.00K | $- | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 85.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $4.24M | $1.12M | $2.43M | $4.27M | $3.41M | $2.85M | $3.57M | $3.35M | $2.21M | $2.22M | $1.52M | $1.90M | $2.58M | $2.66M | $2.21M | $1.91M | $1.04M | $1.49M | $613.08K | $1.48M |
| General and Administrative Expenses | $1.38M | $1.41M | $1.11M | $1.11M | $1.12M | $1.18M | $1.36M | $2.15M | $1.21M | $1.34M | $1.26M | $896.33K | $1.24M | $1.15M | $1.40M | $1.09M | $968.79K | $981.49K | $1.36M | $1.04M |
| Selling and Marketing Expenses | $- | $- | $-818 | $-953 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $1.38M | $1.41M | $1.11M | $1.11M | $1.12M | $1.18M | $1.36M | $2.15M | $1.21M | $1.34M | $1.26M | $896.33K | $1.24M | $1.15M | $1.40M | $1.09M | $968.79K | $981.49K | $1.36M | $1.04M |
| Other Expenses | $- | $- | $- | $- | $- | $- | $- | $4.68M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $9.16K |
| Operating Expenses | $5.63M | $2.53M | $3.54M | $5.38M | $4.53M | $4.03M | $4.93M | $5.50M | $3.42M | $3.56M | $2.78M | $2.79M | $3.81M | $3.81M | $3.61M | $3.00M | $2.01M | $2.47M | $1.97M | $2.52M |
| Cost and Expenses | $5.63M | $2.53M | $3.54M | $5.38M | $4.53M | $4.03M | $4.93M | $5.50M | $3.42M | $3.56M | $2.78M | $2.79M | $3.81M | $3.81M | $3.61M | $3.00M | $2.01M | $2.47M | $1.97M | $2.52M |
| Interest Income | $25.23K | $1.84K | $6.73K | $7.00K | $12.88K | $7.80K | $5 | $2 | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $2.26K | $4.46K | $6.62K | $2.88K | $1.84K | $3.65K | $5.44K | $2.31K | $538 | $1.61K | $2.57K | $2.24K | $947 | $2.35K | $3.75K | $3.26K | $- | $- | $- | $3.62K |
| Depreciation and Amortization | $751 | $752 | $818 | $953 | $899 | $1.00K | $1.28K | $2.38K | $2.79K | $3.21K | $3.38K | $3.49K | $3.37K | $3.21K | $3.00K | $3.14K | $3.16K | $2.87K | $1.92K | $1.09K |
| EBITDA | $-5.60M | $-2.53M | $-3.54M | $-5.37M | $-4.52M | $-4.02M | $-4.93M | $-5.50M | $-3.42M | $-3.56M | $-3.15M | $-2.79M | $-3.81M | $-3.81M | $-3.61M | $-3.00M | $-2.01M | $-2.47M | $-1.97M | $-2.52M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -84539.77% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-5.63M | $-2.53M | $-3.54M | $-5.38M | $-4.53M | $-4.03M | $-4.93M | $-5.50M | $-3.42M | $-3.56M | $-2.78M | $-2.79M | $-3.81M | $-3.81M | $-3.61M | $-3.00M | $-2.01M | $-2.47M | $-1.97M | $-2.52M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -84554.70% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $22.97K | $-2.62K | $106 | $4.12K | $11.04K | $4.15K | $-5.44K | $-369.75K | $-538 | $-1.61K | $-2.57K | $-2.24K | $-947 | $-2.35K | $-3.75K | $-3.26K | $- | $- | $- | $-3.62K |
| Income Before Tax | $-5.61M | $-2.53M | $-3.54M | $-5.38M | $-4.52M | $-4.02M | $-4.93M | $-5.50M | $-3.42M | $-3.57M | $-2.78M | $-2.80M | $-3.81M | $-3.81M | $-3.61M | $-3.00M | $-2.01M | $-2.47M | $-1.97M | $-2.53M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -84489.94% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $- | $- | $2 | $-3 | $12.88K | $7.80K | $10.87K | $2.31K | $538 | $- | $2.57K | $2.24K | $- | $- | $- | $- | $- | $- | $- | $-1.09K |
| Net Income | $-5.61M | $-2.53M | $-3.54M | $-5.38M | $-4.52M | $-4.02M | $-4.93M | $-5.14M | $-3.42M | $-3.57M | $-3.15M | $-3.25M | $-3.81M | $-3.81M | $-3.61M | $-3.00M | $-2.01M | $-2.47M | $-1.97M | $-2.53M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -84489.94% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.25 | $-52.08 | $-57.36 | $-86.99 | $-54.14 | $-51.86 | $-129.35 | $-173.09 | $-131.52 | $-137.15 | $-126.07 | $-191.40 | $-211.91 | $-238.35 | $-225.84 | $-273.17 | $-201.11 | $-247.38 | $-179.48 | $-230.47 |
| EPS Diluted | $-0.25 | $-51.90 | $-57.12 | $-86.62 | $-54.14 | $-51.86 | $-129.35 | $-173.09 | $-128.13 | $-133.62 | $-121.82 | $-175.32 | $-208.48 | $-224.93 | $-219.75 | $-263.73 | $-183.01 | $-225.56 | $-179.48 | $-230.47 |
| Weighted Average Shares Outstanding | 22.18M | 48.59M | 61.80M | 61.80M | 83.54M | 77.55M | 38.13M | 29.68M | 26.00M | 26.00M | 25.00M | 17.00M | 18.00M | 16.00M | 16.00M | 11.00M | 10.00M | 10.00M | 10.97M | 10.97M |
| Weighted Average Shares Outstanding Diluted | 22.18M | 48.76M | 62.06M | 62.06M | 83.54M | 77.55M | 38.13M | 29.68M | 26.69M | 26.69M | 25.87M | 18.56M | 18.30M | 16.95M | 16.44M | 11.39M | 10.99M | 10.97M | 10.97M | 10.97M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $548.72K | $10.06M | $5.00M | $14.04M | $7.24M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $548.72K | $10.06M | $5.00M | $14.04M | $7.24M |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $1.04M | $5.02M | $2.47M | $1.46M | $652.62K |
| Total Current Assets | $1.59M | $12.56M | $7.48M | $15.50M | $7.89M |
| Property Plant Equipment Net | $4.93K | $5.66K | $16.11K | $23.43K | $18.16K |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $104.75K | $482.81K | $1.26M | $334.14K | $-0 |
| Total Non-Current Assets | $109.68K | $488.47K | $1.28M | $357.57K | $18.16K |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $1.70M | $13.05M | $8.76M | $15.85M | $7.91M |
| Account Payables | $5.83M | $3.68M | $1.98M | $946.33K | $289.50K |
| Short Term Debt | $300.81K | $409.97K | $387.79K | $439.29K | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $- | $828.39K | $224.95K | $519.80K | $21.50K |
| Total Current Liabilities | $6.13M | $4.92M | $2.14M | $1.91M | $311.00K |
| Long Term Debt | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $- | $4.09M | $- | $- | $- |
| Other Liabilities | $- | $-4.09M | $- | $- | $- |
| Total Liabilities | $6.13M | $4.92M | $2.14M | $1.91M | $311.00K |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $6.21K | $1.62K | $27.93K | $23.86K | $16.45K |
| Retained Earnings | $-69.57M | $-50.72M | $-34.98M | $-20.95M | $-11.49M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $-0 | $-0 |
| Other Total Stockholders Equity | $65.13M | $58.85M | $41.60M | $34.87M | $19.07M |
| Total Stockholders Equity | $-4.43M | $8.13M | $6.62M | $13.95M | $7.60M |
| Total Equity | $-4.43M | $8.13M | $6.62M | $13.95M | $7.60M |
| Total Liabilities and Stockholders Equity | $1.70M | $13.05M | $8.76M | $15.85M | $7.91M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $1.70M | $13.05M | $8.76M | $15.85M | $7.91M |
| Total Investments | $- | $- | $- | $- | $- |
| Total Debt | $300.81K | $409.97K | $387.79K | $439.29K | $- |
| Net Debt | $-247.91K | $-9.65M | $-4.62M | $-13.60M | $-7.24M |
Balance Sheet Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $6.97M | $1.49M | $815.23K | $548.72K | $909.55K | $4.28M | $5.11M | $10.06M | $7.03M | $8.96M | $12.44M | $5.00M | $8.33M | $6.89M | $11.08M | $14.04M | $1.31M | $2.63M | $5.38M | $7.24M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $6.97M | $1.49M | $815.23K | $548.72K | $909.55K | $4.28M | $5.11M | $10.06M | $7.03M | $8.96M | $12.44M | $5.00M | $8.33M | $6.89M | $11.08M | $14.04M | $1.31M | $2.63M | $5.38M | $7.24M |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $3.70M | $132.65K | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $414.97K | $653.84K | $786.05K | $1.88M | $1.15M | $1.79M | $1.86M | $5.02M | $1.67M | $2.44M | $2.29M | $2.47M | $2.83M | $3.30M | $1.58M | $1.46M | $1.21M | $1.33M | $808.75K | $652.62K |
| Total Current Assets | $7.39M | $2.15M | $1.60M | $1.39M | $2.06M | $6.07M | $6.97M | $12.56M | $8.70M | $11.40M | $14.73M | $7.48M | $11.16M | $13.88M | $12.79M | $15.50M | $2.52M | $3.95M | $6.19M | $7.89M |
| Property Plant Equipment Net | $2.80K | $3.55K | $4.30K | $4.93K | $3.47K | $3.38K | $4.38K | $5.66K | $8.52K | $10.97K | $12.73K | $16.11K | $17.53K | $20.89K | $24.11K | $23.43K | $28.16K | $31.32K | $22.66K | $18.16K |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $18.37K | $320.32K | $55.30K | $307.61K | $262.73K | $377.20K | $438.13K | $482.81K | $929.04K | $1.04M | $1.13M | $1.26M | $334.14K | $334.14K | $334.14K | $334.14K | $440.90K | $- | $- | $- |
| Total Non-Current Assets | $21.18K | $323.87K | $59.60K | $312.54K | $266.20K | $380.58K | $442.52K | $488.47K | $937.56K | $1.05M | $1.14M | $1.28M | $351.66K | $355.03K | $358.24K | $357.57K | $469.06K | $31.32K | $22.66K | $18.16K |
| Other Assets | $- | $- | $- | $1 | $0 | $- | $-0 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $7.41M | $2.47M | $1.66M | $1.70M | $2.33M | $6.45M | $7.41M | $13.05M | $9.64M | $12.45M | $15.87M | $8.76M | $11.51M | $14.24M | $13.14M | $15.85M | $2.99M | $3.99M | $6.21M | $7.91M |
| Account Payables | $- | $6.64M | $5.88M | $5.83M | $4.03M | $3.57M | $2.78M | $3.68M | $1.01M | $490.89K | $489.72K | $1.52M | $1.46M | $892.49K | $1.06M | $946.33K | $250.18K | $150.51K | $141.25K | $289.50K |
| Short Term Debt | $31.19K | $123.25K | $213.10K | $300.81K | $41.90K | $166.40K | $289.07K | $409.97K | $39.26K | $156.40K | $272.57K | $387.79K | $44.63K | $177.58K | $309.13K | $439.29K | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $-5.88M | $- | $-4.03M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $4.03M | $- | $- | $- | $- | $260.14K | $853.23K | $828.39K | $200.00K | $276.57K | $307.01K | $224.95K | $901.22K | $760.68K | $534.94K | $519.80K | $260.60K | $110.69K | $194.79K | $21.50K |
| Total Current Liabilities | $4.06M | $6.76M | $6.09M | $6.13M | $4.07M | $4.00M | $3.92M | $4.92M | $1.24M | $923.86K | $1.07M | $2.14M | $2.41M | $1.83M | $1.90M | $1.91M | $510.78K | $261.20K | $336.04K | $311.00K |
| Long Term Debt | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $3.07M | $4.09M | $1.04M | $- | $762.29K | $1.91M | $1.51M | $1.07M | $1.37M | $1.39M | $250.18K | $150.51K | $191.25K | $289.50K |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $-3.07M | $-4.09M | $-1.04M | $- | $-762.29K | $-1.91M | $-1.51M | $-1.07M | $-1.37M | $-1.39M | $-250.18K | $-150.51K | $-191.25K | $-289.50K |
| Total Liabilities | $4.06M | $6.76M | $6.09M | $6.13M | $4.07M | $4.00M | $3.92M | $4.92M | $1.24M | $923.86K | $1.07M | $2.14M | $2.41M | $1.83M | $1.90M | $1.91M | $510.78K | $261.20K | $336.04K | $311.00K |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $0 | $- | $- | $0 | $0 |
| Common Stock | $33.45K | $1.44K | $10.67K | $6.21K | $4.21K | $4.14K | $2.23K | $1.62K | $40.03K | $40.03K | $40.03K | $27.93K | $27.46K | $27.38K | $25.35K | $23.86K | $16.65K | $16.45K | $16.45K | $16.45K |
| Retained Earnings | $-81.25M | $-75.64M | $-73.11M | $-69.57M | $-64.19M | $-59.67M | $-55.65M | $-50.72M | $-44.75M | $-41.33M | $-37.77M | $-34.98M | $-32.19M | $-28.37M | $-24.56M | $-20.95M | $-17.94M | $-15.93M | $-13.46M | $-11.49M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $- | $- | $- | $- | $- | $-0 | $- | $- | $- | $- | $- | $- | $-0 | $- | $- | $-0 | $-0 |
| Other Total Stockholders Equity | $84.57M | $71.35M | $68.67M | $65.13M | $62.45M | $62.12M | $59.14M | $58.85M | $53.11M | $52.82M | $52.53M | $41.58M | $41.26M | $40.75M | $35.78M | $34.87M | $20.40M | $19.64M | $19.32M | $19.07M |
| Total Stockholders Equity | $3.35M | $-4.29M | $-4.43M | $-4.43M | $-1.74M | $2.45M | $3.49M | $8.13M | $8.39M | $11.52M | $14.80M | $6.62M | $9.10M | $12.41M | $11.24M | $13.95M | $2.47M | $3.72M | $5.88M | $7.60M |
| Total Equity | $3.35M | $-4.29M | $-4.43M | $-4.43M | $-1.74M | $2.45M | $3.49M | $8.13M | $8.39M | $11.52M | $14.80M | $6.62M | $9.10M | $12.41M | $11.24M | $13.95M | $2.47M | $3.72M | $5.88M | $7.60M |
| Total Liabilities and Stockholders Equity | $7.41M | $2.47M | $1.66M | $1.70M | $2.33M | $6.45M | $7.41M | $13.05M | $9.64M | $12.45M | $15.87M | $8.76M | $11.51M | $14.24M | $13.14M | $15.85M | $2.99M | $3.99M | $6.21M | $7.91M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $7.41M | $2.47M | $1.66M | $1.70M | $2.33M | $6.45M | $7.41M | $13.05M | $9.64M | $12.45M | $15.87M | $8.76M | $11.51M | $14.24M | $13.14M | $15.85M | $2.99M | $3.99M | $6.21M | $7.91M |
| Total Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Debt | $31.19K | $123.25K | $213.10K | $300.81K | $41.90K | $166.40K | $289.07K | $409.97K | $39.26K | $156.40K | $272.57K | $387.79K | $44.63K | $177.58K | $309.13K | $439.29K | $- | $- | $- | $- |
| Net Debt | $-6.94M | $-1.37M | $-602.12K | $-247.91K | $-867.64K | $-4.11M | $-4.82M | $-9.65M | $-6.99M | $-8.80M | $-12.17M | $-4.62M | $-8.28M | $-6.71M | $-10.77M | $-13.60M | $-1.31M | $-2.63M | $-5.38M | $-7.24M |
Annual Cash Flow
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Net Income | $-18.85M | $-15.27M | $-14.04M | $-9.46M | $-3.88M |
| Depreciation and Amortization | $4.13K | $11.76K | $13.07K | $11.10K | $1.96K |
| Deferred Income Tax | $- | $- | $-714.87K | $- | $- |
| Stock Based Compensation | $1.01M | $1.20M | $1.72M | $1.29M | $477.10K |
| Change in Working Capital | $3.70M | $3.16M | $-1.24M | $833.78K | $-425.62K |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $1.32M | $1.70M | $576.49K | $656.83K | $153.61K |
| Other Working Capital | $2.38M | $1.46M | $-1.82M | $176.95K | $-579.23K |
| Other Non Cash Items | $498 | $337.25K | $714.87K | $1.58K | $270.31K |
| Net Cash Provided by Operating Activities | $-14.14M | $-10.56M | $-13.54M | $-7.32M | $-3.55M |
| Investments in Property Plant and Equipment | $-3.90K | $-4.42K | $-5.75K | $-17.95K | $-20.12K |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-3.90K | $-4.42K | $-5.75K | $-17.95K | $-20.12K |
| Debt Repayment | $-438.73K | $- | $- | $-43.08K | $-35.00K |
| Common Stock Issued | $2.32M | $16.04M | $4.65M | $14.22M | $10.29M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $2.76M | $15.61M | $4.51M | $-45.00K | $- |
| Net Cash Used Provided by Financing Activities | $4.64M | $15.61M | $4.51M | $14.13M | $10.26M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-9.51M | $5.05M | $-9.03M | $6.80M | $6.69M |
| Cash at End of Period | $548.72K | $10.06M | $5.00M | $14.04M | $7.24M |
| Cash at Beginning of Period | $10.06M | $5.00M | $14.04M | $7.24M | $555.13K |
| Operating Cash Flow | $-14.14M | $-10.56M | $-13.54M | $-7.32M | $-3.55M |
| Capital Expenditure | $-3.90K | $-4.42K | $-5.75K | $-17.95K | $-20.12K |
| Free Cash Flow | $-14.14M | $-10.56M | $-13.54M | $-7.34M | $-3.57M |
Cash Flow Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-5.61M | $-2.53M | $-3.54M | $-5.38M | $-4.52M | $-4.02M | $-4.93M | $-5.50M | $-3.42M | $-3.57M | $-2.78M | $-2.80M | $-3.81M | $-3.81M | $-3.61M | $-3.00M | $-2.01M | $-2.47M | $-1.97M | $-2.53M |
| Depreciation and Amortization | $751 | $752 | $818 | $953 | $899 | $1.00K | $1.28K | $2.38K | $2.79K | $3.21K | $3.38K | $3.49K | $3.37K | $3.21K | $3.00K | $3.14K | $3.16K | $2.87K | $1.92K | $1.09K |
| Deferred Income Tax | $- | $- | $- | $-234.58K | $- | $498.36K | $-1.19M | $- | $- | $- | $- | $-835.37K | $- | $- | $- | $-833.78K | $- | $- | $- | $- |
| Stock Based Compensation | $271.78K | $234.34K | $202.93K | $232.68K | $194.76K | $289.67K | $290.31K | $289.72K | $289.72K | $286.84K | $336.69K | $316.91K | $506.65K | $469.61K | $430.68K | $362.95K | $365.01K | $323.22K | $242.21K | $190.32K |
| Change in Working Capital | $-794.39K | $645.26K | $149.13K | $2.61M | $950.06K | $327.79K | $-184.24K | $2.57M | $1.31M | $-88.10K | $-632.92K | $-762.05K | $1.31M | $-1.66M | $-128.33K | $1.19M | $369.22K | $-594.81K | $-131.08K | $-184.21K |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $132.65K | $- | $-132.65K | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $- | $46.14K | $1.43M | $- | $790.03K | $-901.30K | $2.22M | $514.16K | $1.17K | $-1.03M | $61.25K | $569.08K | $-165.19K | $111.35K | $696.15K | $99.67K | $-40.73K | $-98.25K | $-5.87K |
| Other Working Capital | $-794.39K | $645.26K | $149.13K | $2.61M | $950.06K | $-462.24K | $901.30K | $354.02K | $798.95K | $-89.27K | $400.19K | $-823.30K | $739.74K | $-1.49M | $-239.68K | $494.31K | $269.55K | $-554.08K | $-32.83K | $-178.34K |
| Other Non Cash Items | $-672.19K | $- | $204.38K | $234.32K | $757 | $-498.36K | $1.19M | $334.61K | $1.17K | $2.64K | $1.38M | $835.37K | $-55.70K | $641.22K | $457.97K | $835.37K | $99.67K | $-40.73K | $-98.25K | $44.57K |
| Net Cash Provided by Operating Activities | $-6.80M | $-1.65M | $-3.19M | $-2.54M | $-3.38M | $-3.40M | $-4.82M | $-2.31M | $-1.81M | $-3.36M | $-3.08M | $-3.24M | $-2.00M | $-5.00M | $-3.31M | $-1.45M | $-1.27M | $-2.74M | $-1.86M | $-2.48M |
| Investments in Property Plant and Equipment | $-3 | $3 | $- | $-2.16K | $-1.74K | $- | $- | $1 | $-1.51K | $-2.91K | $- | $-2.08K | $- | $- | $-3.67K | $- | $- | $-11.54K | $-6.41K | $-11.74K |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-6.41K | $- |
| Net Cash Used for Investing Activities | $- | $- | $- | $-2.16K | $-1.74K | $- | $- | $1 | $-1.51K | $-2.91K | $- | $-2.08K | $- | $- | $-3.67K | $- | $- | $-11.54K | $-6.41K | $-11.74K |
| Debt Repayment | $-92.06K | $- | $- | $- | $-124.49K | $- | $-120.89K | $- | $-117.14K | $- | $- | $-82.83K | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $12.41M | $2.42M | $3.53M | $215.64K | $132.85K | $1.97M | $609 | $5.41M | $- | $- | $10.63M | $9.57M | $3.57M | $939.86K | $144.84K | $14.22M | $- | $- | $- | $8.79M |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-40.00K | $2.33M | $3.46M | $2.18M | $- | $2.57M | $609 | $5.33M | $- | $-116.17K | $10.51M | $- | $3.44M | $808.31K | $347.43K | $14.18M | $-45.00K | $- | $- | $41.52K |
| Net Cash Used Provided by Financing Activities | $12.28M | $2.33M | $3.46M | $2.18M | $8.36K | $2.57M | $-120.28K | $5.33M | $-117.14K | $-116.17K | $10.51M | $-82.83K | $3.44M | $808.31K | $347.43K | $14.18M | $-45.00K | $- | $- | $8.83M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $5.48M | $676.33K | $266.50K | $-360.83K | $-3.37M | $-831.28K | $-4.94M | $3.03M | $-1.93M | $-3.48M | $7.44M | $-3.32M | $1.44M | $-4.19M | $-2.96M | $12.73M | $-1.32M | $-2.75M | $-1.86M | $6.34M |
| Cash at End of Period | $6.97M | $1.49M | $815.23K | $548.72K | $909.55K | $4.28M | $5.11M | $10.06M | $7.03M | $8.96M | $12.44M | $5.00M | $8.33M | $6.89M | $11.08M | $14.04M | $1.31M | $2.63M | $5.38M | $7.24M |
| Cash at Beginning of Period | $1.49M | $815.23K | $548.72K | $909.55K | $4.28M | $5.11M | $10.06M | $7.03M | $8.96M | $12.44M | $5.00M | $8.33M | $6.89M | $11.08M | $14.04M | $1.31M | $2.63M | $5.38M | $7.24M | $899.51K |
| Operating Cash Flow | $-6.80M | $-1.65M | $-3.19M | $-2.54M | $-3.38M | $-3.40M | $-4.82M | $-2.31M | $-1.81M | $-3.36M | $-3.08M | $-3.24M | $-2.00M | $-5.00M | $-3.31M | $-1.45M | $-1.27M | $-2.74M | $-1.86M | $-2.48M |
| Capital Expenditure | $-3 | $3 | $- | $-2.16K | $-1.74K | $- | $- | $1 | $-1.51K | $-2.91K | $- | $-2.08K | $- | $- | $-3.67K | $- | $- | $-11.54K | $-6.41K | $-11.74K |
| Free Cash Flow | $-6.80M | $-1.65M | $-3.19M | $-2.54M | $-3.38M | $-3.40M | $-4.82M | $-2.31M | $-1.81M | $-3.37M | $-3.08M | $-3.24M | $-2.00M | $-5.00M | $-3.31M | $-1.45M | $-1.27M | $-2.75M | $-1.86M | $-2.49M |
CNS Pharmaceuticals Dividends
Explore CNS Pharmaceuticals's dividend history, including dividend yield, payout ratio, and historical payments.
CNS Pharmaceuticals News
Read the latest news about CNS Pharmaceuticals, including recent articles, headlines, and updates.
CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme
Berubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints, but not a statistically significant difference in overall survival, the primary endpoint. The safety profile continues to be favorable, including the absence of anthracycline related cardiotoxicity.
CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing
Cash on hand provides over one year of runway to fund expected operations HOUSTON, TX / ACCESS Newswire / February 26, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today provided an update on its current cash position and discussed the completion of its recent initiative to maintain its listing on the NASDAQ Capital Market ("NASDAQ"). "As we kick off 2025, the Company has never been fundamentally stronger.
CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum
Webcast presentation Wednesday, February 26th at 3:20 PM CET HOUSTON, TX / ACCESS Newswire / February 20, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the 18th Annual European Life Sciences CEO Forum on Wednesday, February 26, 2025 at 3:20 PM CET / 9:20 AM EST in Zurich, Switzerland. In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
On-demand video webcast now available here HOUSTON, TX / ACCESS Newswire / February 19, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it participated in the Virtual Investor "Top 5 for ‘25" On-Demand Conference. As part of the event, John Climaco, Chief Executive Officer of CNS Pharmaceuticals, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to the Company in 2025.
CNS Pharmaceuticals Announces Reverse Stock Split
HOUSTON, TX / ACCESS Newswire / February 19, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced a 1-for-50 reverse split of its common stock. Beginning on February 21, 2025, the Company's common stock will continue to trade on The Nasdaq Capital Market ("Nasdaq") on a split adjusted basis under the trading symbol "CNSP", but will trade under the following new CUSIP number: 18978H409.
CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit
HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will present at the 6th Glioblastoma Drug Development Summit being held February 18-20, 2025 in Boston, MA. As part of the event, Sandra Silberman, MD, PhD, Chief Medical Officer of CNS will give an oral presentation titled, "The Use of Traditional Chemotherapy with Activity In the Treatment of Glioblastoma: Novel Formulations of an Anthracylcine & a Taxane That Appear to Cross the Blood-Brain Barrier," on Thursday, February 20, 2025 at 10:45 AM ET.
CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference
In-person presentation today, February 10th at 1:15 PM ET HOUSTON, TX / ACCESS Newswire / February 10, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the BIO CEO & Investor Conference being held February 10-11, 2025 in New York, NY. Details of the presentation are as follows: Date: Monday, February 10, 2025 Presentation Time: 1:15 PM ET Location: Royale Room In addition to the presentation, management will be available to conduct one-on-one meetings and conference attendees that would like to schedule a meeting with the Company are encouraged to register through the BIO CEO attendee portal.
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024
Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion Leaders Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure Register for the event here HOUSTON, TX / ACCESSWIRE / December 5, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will host a Virtual Analyst & Investor Day on Wednesday, December 11th from 11:30 AM - 1:00 PM ET. For the event, John Climaco, Chief Executive Officer, Sandra Silberman, MD, PhD, Chief Medical Officer and Zena Muzyczenko, Vice President of Clinical Operations at CNS Pharmaceuticals will be joined by Key Opinion Leaders: Michael Weller, Prof.
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
Poster presented at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024) Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025 HOUSTON, TX / ACCESSWIRE / November 25, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the presentation of updated results from the on-going potentially pivotal study evaluating Berubicin, the Company's novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier, in a randomized, controlled study vs. Lomustine, which has been considered to be a standard of care in this recurrent glioblastoma population.
CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)
HOUSTON, TX / ACCESSWIRE / November 18, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its abstract has been selected for poster presentation at the 29th Annual Meeting of the Society for Neuro-Oncology being held November 21-24, 2024 in Houston, TX. Details of the presentation are as follows: Title: Update on a Potentially Pivotal Trial CNS-201: A Randomized, Controlled Trial of Berubicin Vs.
CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results
Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025 Company strengthens cash position to extend runway to fund operations beyond data readout of Berubicin potentially pivotal GBM study Quarter marked by pipeline expansion with in-license of TPI 287, a late stage novel potential blood brain barrier permeable abeotaxane for treatment of brain malignancies HOUSTON, TX / ACCESSWIRE / November 15, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the third quarter 2024 ended September 30, 2024. "Our team has made nothing short of transformational advancements throughout 2024.
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment
Segment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael Weller Access the segment here HOUSTON, TX / ACCESSWIRE / November 4, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it participated in a Virtual Investor KOL Connect segment. As part of the event, Professor Michael Weller, a leading Neuro-oncologist who currently serves as the Chairman of the Department of Neurology at the University Hospital in Zurich, Switzerland and as the National Coordinating Investigator for CNS Pharmaceuticals' potentially pivotal study of Berubicin, discussed the unmet need in glioblastoma multiforme (GBM), the current treatment landscape and the potential for Berubicin to provide a solution for this devasting disease.
CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
HOUSTON, TX / ACCESSWIRE / November 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that on October 30, 2024, it received notice from The Nasdaq Hearings Panel that the Company has been granted an exception until March 11, 2025, to regain compliance with the minimum bid price requirement in Listing Rule 5550(a)(2). About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.
CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
HOUSTON, TX / ACCESSWIRE / October 23, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 17,647,060 shares of common stock (or common stock equivalents in lieu thereof) pursuant to a registered direct offering priced at-the-market under Nasdaq rules at a purchase price of $0.17 per share. The closing of the offering is expected to occur on or about October 24, 2024, subject to the satisfaction of customary closing conditions.
CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment
Segment featuring members of the CNS management team and leading Neuro-Oncologist and Key Opinion Leader, Dr. Samuel Goldlust Access the segment here HOUSTON, TX / ACCESSWIRE / October 10, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it participated in a Virtual Investor KOL Connect segment. The segment can be accessed here.
CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC
Live webcast fireside chat on Wednesday, October 16th at 4:00 PM ET HOUSTON, TX / ACCESSWIRE / October 8, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals, will participate in a fireside chat at the 2024 Healthcare Virtual Summit, presented by Maxim Group LLC on October 16,2024 at 4:00 PM ET. Maxim Senior Analysts will host a wide range of biotechnology, diagnostic, medical device, and healthcare information technology companies in a series of presentations and interactive discussions with CEOs and key management.
CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum
Webcast presentation on Wednesday, September 25th at 1:55 PM CEST HOUSTON, TX / ACCESSWIRE / September 23, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the 24th Annual Biotech in Europe Forum on Wednesday, September 25, 2024 at 1:55 PM CEST in Basel, Switzerland. In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement
HOUSTON, TX / ACCESSWIRE / September 12, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that on September 10, 2024, it received notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the equity requirement under Nasdaq's Listing Rule 5550(b)(1), subject to Nasdaq Mandatory Panel Monitor related to the equity requirement for a period of one year. Now that the Company has regained compliance with Listing Rule 5550(b)(1), Nasdaq has advised the Company that this matter is now closed.
CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
HOUSTON, TX / ACCESSWIRE / September 4, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York, NY.
IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.
LOS ANGELES, Sept. 03, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Live webcast on Wednesday, August 28th at 3:20 PM ET HOUSTON, TX / ACCESSWIRE / August 27, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, will present and discuss recent corporate events at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, August 28, 2024 at 3:20 PM ET.
CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment
Live moderated webcast with John Climaco, Chief Executive Officer of CNS Pharmaceuticals on Monday, August 26th at 12:00 PM ET Participants have the ability to submit questions live during the Q&A portion of the segment or pre-submit questions in advan ce of the segment by emailing cnsp@jtcir.com HOUSTON, TX / ACCESSWIRE / August 22, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will participate in a Virtual Investor CEO Connect segment on Monday, August 26, 2024 at 12:00 PM ET. As part of the virtual event, Mr.
CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results
Potentially pivotal GBM study evaluating lead program, Berubicin, enrollment completed; Topline data expected in the first half of 2025 Recent strategic in-license of TPI 287 is highly synergistic with the ongoing potentially pivotal Berubicin program and demonstrates further commitment to changing the treatment paradigm in GBM Company plans to engage the U.S. FDA to seek guidance on advancing TPI 287 into a potential registration study for recurrent GBM Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure HOUSTON, TX / ACCESSWIRE / August 15, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the second quarter 2024 ended June 30, 2024. "It has been an important year for CNS Pharmaceuticals with completion of enrollment in our Berubicin trial, and more recently, our in-licensing of a highly synergistic asset for development, TPI 287.
Why Is CNS Pharmaceuticals (CNSP) Stock Down 69% Today?
CNS Pharmaceuticals (NASDAQ: CNSP ) stock is heading lower on Tuesday after the clinical-pharmaceutical company announced an expansion to its pipeline. CNS Pharmaceuticals has acquired an exclusive license and the intellectual property rights to TPI 287.
CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies
Strategic in-license from Cortice Bioscience is highly synergistic with the ongoing potentially pivotal Berubicin program and demonstrates further commitment to changing the treatment paradigm in GBM Drug candidate, TPI 287, awarded Orphan designation and studied in over 350 patients to date, including clinical trials as monotherapy and in combination with bevacizumab demonstrating encouraging clinical efficacy and safety profile at target therapeutic doses Company plans to engage the U.S. FDA to seek guidance on advancing TPI 287 into a potential registration study for recurrent GBM Leveraging the significant clinical infrastructure and deep relationships established with the Neuro-Oncology community to expedite development of TPI 287 Company launches new corporate brand and website to more closely align with its unwavering commitment to addressing the most aggressive type of brain cancer, GBM, with an average survival of only 14 to 16 months after diagnosis and no cure Company to host live video webcast to discuss the transaction today, July 30 th at 8:30 AM ET HOUSTON, TX / ACCESSWIRE / July 30, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it has entered into an exclusive license agreement with Cortice Biosciences, Inc. ("Cortice"). The Company will host a live webcast presentation to discuss the transaction on Tuesday, July 30, 2024 at 8:30 AM ET (details below).
CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference
HOUSTON, TX / ACCESSWIRE / July 25, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its abstract has been selected for poster presentation at the 2024 SNO/ASCO CNS Cancer Conference being held August 8-10, 2024 in Denver, CO. Details of the presentation are as follows: Title: Use of a Brain-Penetrating Anthracycline in Anthracycline-Sensitive Brain Metastases: The Promise of Berubicin Presenter: Sandra Silberman, MD, PhD, Chief Medical Officer of CNS Pharmaceuticals Abstract Code: RMTD-03 Category: Research Methods and Trial Design Considerations Date and Time: August 8, 2024 from 7:15 - 9:00 PM MT Location: Plaza Exhibit Hall, Sheraton Denver Downtown Hotel For more information about the event, please visit the conference website.
CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series
Live video webcast with Chief Executive Officer, John Climaco, on Wednesday, June 17th at 4:00 PM ET HOUSTON, TX / ACCESSWIRE / July 16, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will participate in the Virtual Investor Closing Bell Series on Wednesday, June 17, 2024 at 4:00 PM ET. As part of the event, Mr.
CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement
HOUSTON, TX / ACCESSWIRE / July 3, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has entered into securities purchase agreements with health-care focused institutional investors for the purchase and sale of 1,425,000 shares of common stock in a registered direct offering and warrants to purchase up to 1,425,000 shares of common stock in a concurrent private placement (together with the registered direct offering, the "Offering") at a combined purchase price of $1.39 per share. The warrants issued pursuant to the concurrent private placement will have an exercise price of $1.26 per share, will be exercisable immediately following the date of issuance and will expire 5 years from the initial exercise date.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for CNSP.